- CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”)
- GBM is an aggressive form of cancer that occurs in the brain or spinal cord
- In the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosis
- CNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030
On July 24, 2021, pre-clinical stage biotechnology company CNS Pharmaceuticals (NASDAQ: CNSP) received Fast Track Designation from the U.S. Food and Drug Administration (“FDA”) for its Berubicin drug product (https://ibn.fm/fFjF8). Granted to help facilitate the development and expedite the review of drugs being developed to treat serious conditions and fill unmet medical needs, the designation showed the seriousness of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord. The Fast Track status came just over a year after the company had received Orphan Drug Designation (“ODD”), which is intended to support the development and review of novel treatments for rare diseases.
GBM is considered one of the most complex, deadly, and treatment-resistant cancers. And although it is regarded as a rare condition, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (“NBTS”) estimates that over…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.